ClinicalTrials.gov
ClinicalTrials.gov Menu

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01492673
Recruitment Status : Active, not recruiting
First Posted : December 15, 2011
Last Update Posted : April 18, 2018
Sponsor:
Collaborators:
Genentech, Inc.
Children's Mercy Hospital Kansas City
Penn State University
University of Colorado, Denver
Sidney Kimmel Comprehensive Cancer Center
Phoenix Children's Hospital Center for Cancer & Blood Disorders
Alberta Children's Hospital
MD Anderson Cancer Center Orlando
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2019
  Estimated Study Completion Date : December 2019